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PRELIMINARY AND SHORT REPORT
THE EFFECT OF RESERPINE ON URTICARIA PIGMENTOSA*
RUDOLF L. BARR, M.D., ROBERT BEB5ANI, M.D. AND ALFRED PELZIG, M.D.
Marks, Sorgen and Hayes (1) reported that
reserpine produces a loss of granulation and con-
comitantly a release of serotonin in entero-chro-
maffin cells of the rat duodenum. Their investiga-
tions followed those of Benditt and Wong (2) who
had shown that in the guinea pig the number of
stainable enterochromaffin cells diminishes follow-
ing administratiou of reserpine.
Although we were aware of the differences be-
tween the granules of enterochromaffin cells and
mast cells (3) we considered the possibility that
reserpine might also produce degranulation of the
granules of tissue mast cells in man. It was thought
that if such an effect actually occurs, it might
bring about clinically detectable changes in the
lesions of patients with urticaria pigmentosa, as
biologically highly active materials presumably
are contained in these granules. On this basis
reserpine was administered in the following three
cases.
Case 1. A. M., a man aged 68, had widely dis-
seminated macular and papular lesions which
urticated on rubbing. These were said to have been
present for 17 years. The clinical diagnosis of
urticaria pigmentosa had been confirmed by
biopsy. On April 21 reserpine 1 mg daily was pre-
scribed. When he was seen again on May 12, he
reported that 24 hours after he started to take
reserpine he had noted "tremendous" burning
and itching in all the lesions. He had discontinued
taking reserpine after 4 days, but was asked to
resume this medication on May 12. On May 19 he
stated that the burning had not recurred after
resumption of reserpine, but that the whealing
of his lesions generally had decreased. Objectively
no change was seen. On May 28 when he was seen
last, no further change had occurred.
Case 2. A. C., a girl aged 14, had widely dis-
seminated brownish macular lesions which urti-
cated on rubbing. These were said to have been
present for 4 years. The clinical diagnosis of urti-
caria pigmentosa had been confirmed by biopsy.
On June 5 reserpine 0.125 mg daily was prescribed.
No change in the lesions had occurred on June
12 and the dose was increased to 0.25 and 0.125
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mg on alternate days. On June 19 there was defi-
nite fading of the lesions and Darier's sign could
not be elicited. Reserpine dosage was increased to
0.25 mg daily. Improvement was maintained dur-
ing an observation period of 3 months. Side effects
of nocturnal dyspnea and nasal blocking were
noted.
Case 3. J. M., a man aged 56, had widely dis-
seminated macular and papular lesions which
urticated on rubbing. These were said to have been
present for 29 years. The clinical diagnosis of ur-
ticaria pigmentosa had been confirmed by biopsy.
On June 10 he was given reserpine 0.25 mg daily.
On June 17 there was less urtication and on June
30 further objective and subjective improvement
had occurred. No urtication was seen. On Septem-
ber 19 papular lesions were no longer noted and
the macules did not urticate. It appeared that
many of the macules previously seen had faded.
No significant change in blood pressure was
noted in any of the 3 cases during the treatment
with reserpine.
COMMENT
The decrease or disappearance of itching, burn-
ing and whealing, the fading of some of the lesions
in 2 cases and the generalized Herxheimer re-
action-like effect in one case indicate that re-
serpine had an effect on the lesions and subjective
manifestations of the three cases of urticaria pig-
mentosa reported here. Only more extensive trials
will make it possible to ascertain in what per-
centage of cases such effects can be produced with
reserpine. Furthermore without further studies it
cannot be ascertained whether our hypothesis is
correct that reserpine produced the changes,
noted in our patients, by causing degranulation of
the basophilic granules of the tissue mast cells
and if so what substances (e.g. serotonin?) are
released in the process of degranulation.
We would like to point out that it appears in-
advisable to administer reserpine in as high a dose
as 1 mg daily for more than one week. However,
a dose of 0.25 mg daily has been suggested as a safe
maintenance dose (4).
sUMMARY
The effects of reserpine on the lesions and sub-
jective manifestations of three patients with
urticaria pigmentosa are described.
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